Overview
Parkinsonian Syndromes (PDS) with predominant motor dysfunction include progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal degeneration (CBD). Current treatment options for PDS are extremely limited due to the less understanding of disease pathophysiology and lack of therapeutic targets. Combining the results of previous studies and our group's previous research, sixty qualified PDS patients would be enrolled to conduct a prospective single-center randomized sham controlled clinical trial to verify the new therapeutic options that can improve symptoms and effectively slow the progression of the disease.
Eligibility
Inclusion Criteria:
- Compliance with the MDS revised clinical diagnostic criteria for Parkinsonian syndrome (2015 edition)
- aged >40 years and <80 years, regardless of gender.
- Patients were relatively stable during the study period and remained stable on medication
- Good compliance, written informed consent, and consent for NIBS long-term intervention treatment
Exclusion Criteria:
- Patients with severe neuropsychiatric disorders or a previous history of severe neurologic conditions (e.g., epilepsy, cerebrovascular accident, etc.) or traumatic brain injury or brain surgery
- inability to complete the questionnaire independently
- Previous treatment with DBS or SCS; TMS or tDCS within 6 months
- Severe physical illness and any physical condition that can precipitate epilepsy or intracranial hypertension, including cardiovascular and respiratory diseases
- Installation of intracranial stents, pacemakers, coronary stents, cochlear implants, and other human implantable materials
- is currently taking other investigational drugs or is participating in other clinical trials
- Any other condition that the investigator believes makes him or her unsuitable for participation in this study.